A Phase II Time-Limited Approach to Initial Ibrutinib Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Complete or Partial Remission

Share
Print

Full Title

A Phase 2 Time-Limited Approach to Front-Line Ibrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients who Achieve Complete Remission or Partial Remission with Undetectable Minimal Residual Disease

Purpose

Ibrutinib is a medication commonly used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients are usually treated indefinitely or until they have severe side effects from the drug. 

Researchers are doing this study to find out whether patients with CLL or SLL who are receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months if they have achieved complete or partial remission of their disease. They think that stopping treatment with ibrutinib in these patients could reduce the serious side effects and financial costs associated with long-term treatment with this drug.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have been receiving ibrutinib for at least 15 months as initial treatment for CLL or SLL.
  • Patients must be in complete or partial remission (undetectable minimal residual disease).
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anthony Mato at 646-608-3748.

Protocol

20-284

Phase

II

Investigator

Co-Investigators